CA2123094A1 - Cell Culture Medium - Google Patents
Cell Culture MediumInfo
- Publication number
- CA2123094A1 CA2123094A1 CA 2123094 CA2123094A CA2123094A1 CA 2123094 A1 CA2123094 A1 CA 2123094A1 CA 2123094 CA2123094 CA 2123094 CA 2123094 A CA2123094 A CA 2123094A CA 2123094 A1 CA2123094 A1 CA 2123094A1
- Authority
- CA
- Canada
- Prior art keywords
- growth
- differentiation
- serum
- hematopoietic
- free medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
Abstract
A basal serum-free medium and a hematopoietic cell growth and differentiation-promoting serum-free medium based thereon are provided for the maintenance, cultivation, growth and differentiation of erythroid progenitor cells, other hematopoietic progenitor cells, and leukemia cells in which the effects of various growth factor compounds can be quantitatively evaluated.
Both media are wholly serum-free and contain no intrinsic growth factor compounds. The hematopoietic growth and differentiation medium consists essentially of the basal serum-free medium to which has been added at least one primarily but not exclusively growth promoting agent selected from heme or hemin, interleukin-3 and recombinant human stem cell factor (and optimally all of them), and at least one primarily but not exclusively cell differentiation promoting agent selected from erythropoietin (Epo), insulin-like growth factor (IGF) and a retinoid (and optimally including all of them).
Both media are wholly serum-free and contain no intrinsic growth factor compounds. The hematopoietic growth and differentiation medium consists essentially of the basal serum-free medium to which has been added at least one primarily but not exclusively growth promoting agent selected from heme or hemin, interleukin-3 and recombinant human stem cell factor (and optimally all of them), and at least one primarily but not exclusively cell differentiation promoting agent selected from erythropoietin (Epo), insulin-like growth factor (IGF) and a retinoid (and optimally including all of them).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78852791A | 1991-11-06 | 1991-11-06 | |
US788,527 | 1991-11-06 | ||
PCT/CA1992/000481 WO1993009220A1 (en) | 1991-11-06 | 1992-11-05 | Cell culture medium |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2123094A1 true CA2123094A1 (en) | 1993-05-13 |
CA2123094C CA2123094C (en) | 1999-08-10 |
Family
ID=25144763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002123094A Expired - Fee Related CA2123094C (en) | 1991-11-06 | 1992-11-05 | Cell culture medium |
Country Status (4)
Country | Link |
---|---|
US (1) | US5397706A (en) |
AU (1) | AU2882992A (en) |
CA (1) | CA2123094C (en) |
WO (1) | WO1993009220A1 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635387A (en) * | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
US5766951A (en) * | 1992-11-12 | 1998-06-16 | Quality Biological, Inc. | Serum-free medium supporting growth and proliferation of normal bone marrow cells |
NZ314644A (en) | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
WO1995002685A1 (en) * | 1993-07-15 | 1995-01-26 | Applied Immune Sciences, Inc. | Serum-free culture of progenitor cells |
US6190655B1 (en) | 1993-12-03 | 2001-02-20 | Immunex Corporation | Methods of using Flt-3 ligand for exogenous gene transfer |
US7294331B2 (en) * | 1994-03-07 | 2007-11-13 | Immunex Corporation | Methods of using flt3-ligand in hematopoietic cell transplantation |
US7150992B1 (en) | 1995-10-04 | 2006-12-19 | Innunex Corporation | Methods of preparing dendritic cells with flt3-ligand and antigen |
US7361330B2 (en) * | 1995-10-04 | 2008-04-22 | Immunex Corporation | Methods of using flt3-ligand in the treatment of fibrosarcoma |
US20020034517A1 (en) * | 1995-10-04 | 2002-03-21 | Kenneth Brasel | Dendritic cell stimulatory factor |
WO1997033978A1 (en) * | 1996-03-12 | 1997-09-18 | Life Technologies, Inc. | Hematopoietic cell culture nutrient supplement |
US6495365B1 (en) | 1996-08-13 | 2002-12-17 | Fujisawa Pharmaceutical Co., Ltd. | Hematopoietic stem cell proliferating agents |
AU733714B2 (en) * | 1996-08-27 | 2001-05-24 | Hemosol Inc. | Enhanced stimulation of erythropoiesis |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
CA2277278A1 (en) * | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
WO1999067360A2 (en) * | 1998-06-25 | 1999-12-29 | Hemosol Inc. | Media and methods for expansion of erythroid stem cells for the production of hemoglobin |
US6261841B1 (en) * | 1999-06-25 | 2001-07-17 | The Board Of Trustees Of Northwestern University | Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells |
CA2399734A1 (en) * | 2000-02-08 | 2001-08-16 | Ssp Co., Ltd. | Method of detecting ligand or ligand-like low-molecular weight compound |
EP1176189A1 (en) * | 2000-07-21 | 2002-01-30 | Fornix Biosciences N.V. | Stem cell-like cells |
US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
EP1475434A1 (en) | 2003-05-09 | 2004-11-10 | Oncoscience AG | Method for storing tumor cells |
EP1773981A1 (en) * | 2004-07-12 | 2007-04-18 | Sorin Group Italia S.R.L. | Device and method for growing human cells |
US20090169523A1 (en) | 2005-06-13 | 2009-07-02 | Catherine Verfaillie | Hsc self-renewal |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
AU2007261530B2 (en) * | 2006-06-20 | 2014-02-06 | Genzyme Corporation | Serum-free media and their uses for chondrocyte expansion |
ITMI20071421A1 (en) * | 2007-07-16 | 2009-01-17 | Fond Irccs Istituto Di Ricove | CULTURE TO EXPAND EX-LIVE STEM CELLS |
EP2245141B1 (en) | 2008-01-18 | 2018-03-14 | Regents of the University of Minnesota | Stem cell aggregates and methods for making and using |
DK2456853T3 (en) | 2009-07-21 | 2021-02-01 | Abt Holding Co | USE OF STEM CELLS TO REDUCE LEUCOCYT EXTRAVASATION |
SG10201913618WA (en) | 2009-07-21 | 2020-03-30 | Abt Holding Co | Use of stem cells to reduce leukocyte extravasation |
BR112012021451B8 (en) | 2010-02-25 | 2021-05-25 | Abt Holding Co | use of cells that have a desired efficiency for expression and/or secretion of the pro-angiogenic factors vegf, cxcl5 and il8, methods to build a cell bank, to develop drug, and to increase the expression of one or more pro-angiogenic factors angiogenic in a cell performed in vitro, and composition |
SG183497A1 (en) | 2010-02-25 | 2012-09-27 | Abt Holding Co | Modulation of macrophage activation |
CA3128483A1 (en) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy |
WO2011158125A2 (en) | 2010-06-17 | 2011-12-22 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
EP2609191B1 (en) | 2010-08-24 | 2017-11-22 | Regents Of The University Of Minnesota | Non-static suspension culture of cell aggregates |
US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
US9388388B2 (en) | 2011-01-31 | 2016-07-12 | Katholieke Universiteit Leuven | Methods for making cells with an extra-embryonic endodermal precursor phenotype |
JP6182135B2 (en) | 2011-06-06 | 2017-08-16 | レゲネシス ベーフェーベーアー | Amplification of stem cells in a hollow fiber bioreactor |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
GB201119335D0 (en) | 2011-11-09 | 2011-12-21 | Univ Leuven Kath | Hepatitis virus infectable stem cells |
EP2785350B1 (en) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
PT2785834T (en) | 2011-12-02 | 2020-11-13 | Fate Therapeutics Inc | Enhanced stem cell composition |
WO2013121426A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
US20130209431A1 (en) * | 2012-02-13 | 2013-08-15 | New York Blood Center, Inc. | Isolation and culture of erythroid progenitor cells |
WO2013149337A1 (en) | 2012-04-02 | 2013-10-10 | Hydrogenics Corporation | Fuel cell start up method |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
WO2014150602A1 (en) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
SG10201914136UA (en) | 2013-04-12 | 2020-03-30 | Saverio Lafrancesca | Improving organs for transplantation |
US20140322135A1 (en) | 2013-04-30 | 2014-10-30 | Katholieke Universiteit Leuven | Cell therapy for myelodysplastic syndromes |
CN105992816B (en) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
SG10201914102UA (en) | 2016-01-21 | 2020-03-30 | Abt Holding Co | Stem cells for wound healing |
WO2019021321A1 (en) * | 2017-07-28 | 2019-01-31 | Regenerative Medical Services Pvt. Ltd. | Optimized hematopoietic stem cell cfu assay |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560655A (en) * | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
JPS59169489A (en) * | 1983-03-15 | 1984-09-25 | Otsuka Pharmaceut Co Ltd | Cultured and established human cell |
FR2543158B1 (en) * | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | MEDIUM FOR CULTURING ANIMAL CELLS WITHOUT SERUM, WITHOUT HORMONES AND WITHOUT GROWTH FACTORS AND METHODS OF PRIMARY CULTURE AND OF OBTAINING CELL LINES USING THE SAME |
DE3683956D1 (en) * | 1985-06-11 | 1992-04-02 | Us Commerce | HUMAN MONOCYTES CULTIVATED IN A SERUM-FREE MEDIUM IN SUSPENSION. |
US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
FR2600076A1 (en) * | 1986-06-12 | 1987-12-18 | Fond Ctre Nal Transfusion | CULTURE MEDIUM COMPRISING HUMAN ALBUMIN, PROCESS FOR PREPARING A PRODUCT INJECTABLE THEREFROM, PRODUCT OBTAINED AND USE THEREOF, COMPOSITION OBTAINED |
CS262822B1 (en) * | 1986-10-03 | 1989-04-14 | Kovar Jan | Synthetic medium for the cultivation of myelomic cells |
CA1324098C (en) * | 1986-10-20 | 1993-11-09 | Frederick J. Darfler | Serum-free medium for the proliferation of lymphokine-activated killer cells |
JPH0634713B2 (en) * | 1987-08-21 | 1994-05-11 | 萩原 義秀 | Method for culturing human / human hybridoma |
WO1989006694A1 (en) * | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
US5126261A (en) * | 1989-04-12 | 1992-06-30 | Board Of Regents, The University Of Texas System | High calcium chemically defined culture medium |
-
1992
- 1992-11-05 AU AU28829/92A patent/AU2882992A/en not_active Abandoned
- 1992-11-05 CA CA002123094A patent/CA2123094C/en not_active Expired - Fee Related
- 1992-11-05 WO PCT/CA1992/000481 patent/WO1993009220A1/en active Application Filing
-
1993
- 1993-08-06 US US08/103,419 patent/US5397706A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5397706A (en) | 1995-03-14 |
AU2882992A (en) | 1993-06-07 |
WO1993009220A1 (en) | 1993-05-13 |
CA2123094C (en) | 1999-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2123094A1 (en) | Cell Culture Medium | |
Metcalf et al. | Direct proliferative actions of stem cell factor on murine bone marrow cells in vitro: effects of combination with colony-stimulating factors. | |
Kurtz et al. | A new candidate for the regulation of erythropoiesis: Insulin‐like growth factor I | |
AU641488B2 (en) | Human hematopoietic stem cell | |
CA2261292A1 (en) | Chondrocyte media formulations and culture procedures | |
Dexter et al. | The role of cells and their products in the regulation of in vitro stem cell proliferation and granulocyte development | |
CA2220515A1 (en) | Process for producing erythropoietin containing no animal proteins | |
AU4924197A (en) | Biological factors and neural stem cells | |
DE69229572T2 (en) | Glial cell activating factor and its production | |
FI906411A0 (en) | FOERHINDRING AV CELLFOEROEKNING MED DECORIN. | |
AU1745888A (en) | Improvements in and relating to fermentation | |
CA2018228A1 (en) | Cell culture systems and media | |
RS50330B (en) | Process for culturing cells in a monolayer | |
WO1999067360A3 (en) | Media and methods for expansion of erythroid stem cells for the production of hemoglobin | |
EP0513738A3 (en) | Serum-free medium for mammalian cells cultivation | |
UA29377C2 (en) | Method for preparing protein with activity of granulocyte macrophage-colony stimulating factor (gm-csf) of primates | |
IL140479A0 (en) | A microbial culture with tyrosinase activity stabilized by reducing the amount of dissolved oxygen in the medium during tyrosinase expression | |
WO2000043499A3 (en) | ANTI-TRANSFORMING GROWTH FACTOR BETA (TGF-β) TREATED STEM CELL COMPOSITION AND METHOD | |
EP0550769A4 (en) | ||
RU1825377C (en) | Method for producing a 82810 antibiotic or its derivatives and "actinomadura fibrosa" strain - a 82810 antibiotic producer | |
AU1609900A (en) | Method for the massive culture of cells producing recombinant human erythropoietin | |
AU3058489A (en) | Methods for controlling norleucine content in polypeptides | |
ES8802185A1 (en) | Novel polypeptides having growth factor activity and nucleic acid sequences encoding the polypeptides. | |
CA2002210A1 (en) | Expression and processing of authentic fgf's in yeast | |
Oddos et al. | Erythropoiesis in murine long‐term bone‐marrow cell cultures: Dependence on erythropoietin and endogenous production of an erythropoietic stimulating activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20031105 |